Aug 4, 2016
Advancing proprietary and partnered pipeline candidates with Novartis and Regeneron Cash and cash equivalents of approximately $300.7 million to accelerate CRISPR/Cas9 platform and pipeline development CAMBRIDGE, Mass. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Jun 3, 2016
Summary ToggleIntellia Therapeutics to Present at the Jefferies 2016 Healthcare Conference and the International BIO Convention
CAMBRIDGE, Mass. , June 03, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading gene editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at both the upcoming Jefferies 2016 Healthcare Conference and the
May 11, 2016
Underwriters Exercise Over-Allotment Option CAMBRIDGE, Mass. , May 11, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced the closing of its initial public offering of 6,900,000 shares of its common stock at an initial public offering price of $18.00 per share, which
May 5, 2016
CAMBRIDGE, Mass. , May 05, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (”Intellia Therapeutics” or “Intellia”) a leading gene editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced the pricing of its initial public
Apr 22, 2016
CAMBRIDGE, MASS. – April 22, 2016 — Intellia Therapeutics, Inc., a leading gene-editing company, has named Perry Karsen as the Chairman of its Board of Directors. Mr. Karsen held leadership positions at Celgene Corporation, including Chief Operations Officer and Executive Vice President and
Apr 11, 2016
Summary ToggleRegeneron and Intellia Therapeutics Announce Collaboration to Discover and Develop CRISPR/Cas Therapeutics
Tarrytown, New York and Cambridge, Mass. (April 11, 2016) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Intellia Therapeutics, Inc. announced today a licensing and collaboration agreement to advance CRISPR/Cas gene editing technology for in vivo therapeutic development.
Mar 9, 2016
BOSTON, MA – March 9, 2016 – Harvard Medical School announced today that the2016 Warren Alpert Foundation Prize will be awarded to five scientists for the novelgene-editing technology, CRISPR/Cas9. Two of Intellia Therapeutics' founders, Jennifer Doudna and Rodolphe Barrangou , are included among
Jan 12, 2016
Summary ToggleIntellia Therapeutics Launches New Division to Accelerate Ex Vivo Programs with CRISPR/CAS9
Focused on Immuno-Oncology, Autoimmune and Inflammatory Disease Areas Dedicated Scientific Organization and Leadership Team Will Build on Intellia's Expertise with CRISPR/Cas9 – Cambridge, Mass. – January 12, 2016 – Intellia Therapeutics, a leading gene-editing company, has launched a new division,
Dec 14, 2015
Former Chief Financial Officer Brings 30 Years of Business Leadership and Board of Directors' Experience CAMBRIDGE, MASS. – December 14, 2015 — Intellia Therapeutics, Inc., a leading gene-editing company, has named Caroline Dorsa to its Board of Directors .
Dec 1, 2015
Summary ToggleJoint Statement of Intellia Therapeutics & CRISPR Therapeutics: Position Regarding Human Germline Gene Editing
Therapeutic applications of gene editing, including CRISPR/Cas9 and other CRISPR-based technologies, provide an unparalleled opportunity for treating, or even curing, patients with serious genetic disorders. These exciting, recently discovered technologies have the potential to bring new treatments